Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Why the big jump in volume?

<< Previous

Bullboard Posts

Next >>

Post by Moonshiner592on Jun 11, 2021 4:18pm

241 Views

Post# 33373954

Why the big jump in volume?

See that sudden jump in the volume??

The Friday before the vote on the split has Anson trying to sow Fear, Uncertainty and Doubt (FUD) in a desperate attempt to shore up their position so it doesn’t go down the tubes.

Once we have the vote the split will ensure they can’t stop financing and we have so much stuff ready to roll that they will be dust eating our dust as we move onto different phases and multiple applications for our R-107 drug.

<< Previous

Bullboard Posts

Next >>

Soma Gold poised to extend profitable track record